Clinical Trial Update: Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 [Phase 3]

View source ↗

Summary

This document reports on a global open-label extension study (Phase 3) evaluating Del-desiran for myotonic dystrophy type 1, with enrollment currently by invita…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Del-desiran (del-desiran)

Snippet

Sponsor: Avidity Biosciences, Inc. | Conditions: Myotonic Dystrophy Type 1, DM1 | Phase 3 | Status: ENROLLING_BY_INVITATION